Trial Profile

A phase 1 clinical trial to evaluate the safety and tolerability of URC-102 in healthy Chinese people

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs URC 102 (Primary)
Indications Gout
Focus Adverse reactions

Most Recent Events

10 Dec 2020 New trial record
02 Dec 2020 According to a JW Pharmaceutical media release, this trial will be conducted at Shanghai Public Health Clinical Center.
02 Dec 2020 According to a JW Pharmaceutical media release, National Medical Products Administration (NMPA) of China approved the clinical trial application to proceed with this trial. IND was submitted in August this year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com